Christopher Zochowski

Christopher Zochowski, a Private Investor, asked about the current quarter's defense business volatility and the potential for increased NRE revenues to drive future non-defense business. He also inquired about market gains and new device applications stemming from the two-year Abbott agreement, and sought clarification on NVE's medical customer applications, particularly the need for tiny parts in medical robotics.

Answer

Peter Eames, VP of Advanced Technology, expressed optimism for a return to normal flow in the defense business after a period of weakness. Dan Baker, President and CEO, confirmed that R&D investments, especially in miniaturization, aim to convert NRE revenues into future sales. He noted confidentiality restrictions regarding specific Abbott devices but highlighted NVE's role in various medical products, including life support, non-life support, and instruments, emphasizing how small, high-sensitivity sensors enhance precision in medical robots.